Source comparison
TB-500 Research Tendon Studies: Timeline & Outcome Measurement Comparison
TB-500 Dose Range 5-10mg twice weekly 10-15mg twice weekly 15-20mg daily Chronic injuries require higher cumulative doses due to established fibrosis Primary Outcome Measure Inflammatory marker reduction (IL-6, TNF-α) Collagen alignment via polarized light mic
This comparison does not assign a generated winner or score.
- TB-500 Dose Range
- 5-10mg twice weekly
- 10-15mg twice weekly
- 15-20mg daily
- Chronic injuries require higher cumulative doses due to established fibrosis
- Primary Outcome Measure
- Inflammatory marker reduction (IL-6, TNF-α)
- Collagen alignment via polarized light microscopy
- Tensile strength testing
- Each phase requires different analytical methods to capture mechanism-specific effects
- Expected Effect Size
- 15-25% reduction in inflammatory markers at 48hrs
- 30-40% improvement in collagen fiber alignment at 14 days
- 10-20% improvement in ultimate tensile strength at 60 days
- Effect sizes diminish as healing progresses. Early intervention shows larger differences
- Control Requirements
- Saline control + untreated control
- Saline control mandatory, platelet-rich plasma comparison recommended
- Surgical repair alone vs TB-500 + surgical repair
- Chronic models require active treatment controls to isolate TB-500-specific effects
- The Bottom Line: TB-500's documented effects on tendon healing are time-dependent and phase-specific. Research teams must align dosing protocols, outcome measures, and analysis timelines with the specific healing phase being studied. A protocol optimized for acute inflammation won't capture the collagen remodeling effects relevant to subacute or chronic tendon injuries.